Antigen specificity can be irrelevant to immunocytokine efficacy and biodistribution

Proceedings of the National Academy of Sciences of the United States of America

Volumn 112, Issue 11, 2015, Pages 3320-3325

  Tzeng, Alice ^a,b   Kwan, Byron H ^a,b   Opel, Cary F ^a,b   Navaratna, Tejas ^a   Wittrup, K Dane ^a,b  

^a Massachusetts Institute of Technology Cambridge   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

Antibody; Biodistribution; IL 2; Immunocytokine; Immunotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; CANCER ANTIBODY; FC RECEPTOR; IMMUNOCYTOKINE; INTERLEUKIN 2 IMMUNOCYTOKINE; INTERLEUKIN 2 RECEPTOR; PROTEIN; TA99 ANTIBODY; TRP1 PROTEIN; UNCLASSIFIED DRUG; EPITOPE; HYBRID PROTEIN; INTERLEUKIN 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CONTROL; COMPLEMENT DEPENDENT CYTOTOXICITY; CONTROLLED STUDY; CYTOKINE RESPONSE; DOSE TIME EFFECT RELATION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENTIATION; DRUG RECEPTOR BINDING; IN VITRO STUDY; IN VIVO STUDY; INNATE IMMUNITY; MELANOMA; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN PROTEIN INTERACTION; TUMOR MICROENVIRONMENT; TUMOR MODEL; ANIMAL; BIOLOGICAL MODEL; C57BL MOUSE; DRUG EFFECTS; IMMUNOLOGY; MELANOMA, EXPERIMENTAL; METABOLISM; TISSUE DISTRIBUTION; TREATMENT OUTCOME;

ANIMALS; ANTIBODIES, NEOPLASM; ANTINEOPLASTIC AGENTS; EPITOPES; IMMUNITY, INNATE; INTERLEUKIN-2; MELANOMA, EXPERIMENTAL; MICE, INBRED C57BL; MODELS, IMMUNOLOGICAL; RECEPTORS, IGG; RECOMBINANT FUSION PROTEINS; TISSUE DISTRIBUTION; TREATMENT OUTCOME;

EID: 84925424460     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1416159112     Document Type: Article

References (35)

1. Pasche N, Neri D (2012) Immunocytokines: A novel class of potent armed antibodies. Drug Discov Today 17(11-12):583-590.
2. Sondel PM, Gillies SD (2012) Current and potential uses of immunocytokines as cancer immunotherapy. Antibodies (Basel) 1(2):149-171.
3. Rosenberg SA (2014) IL-2: The first effective immunotherapy for human cancer. J Immunol 192(12):5451-5458.
4. Becker JC, Pancook JD, Gillies SD, Furukawa K, Reisfeld RA (1996) T cell-mediated eradication of murine metastatic melanoma induced by targeted interleukin 2 therapy. J Exp Med 183(5):2361-2366.
5. Gillies SD, et al. (2011) A low-toxicity IL-2-based immunocytokine retains antitumor activity despite its high degree of IL-2 receptor selectivity. Clin Cancer Res 17(11):3673-3685.
6. Schliemann C, et al. (2009) Complete eradication of human B-cell lymphoma xenografts using rituximab in combination with the immunocytokine L19-IL2. Blood 113(10):2275-2283.
7. Gillies SD, et al. (2005) An anti-CD20-IL-2 immunocytokine is highly efficacious in a SCID mouse model of established human B lymphoma. Blood 105(10):3972-3978.
8. Shusterman S, et al. (2010) Antitumor activity of hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: A Children's Oncology Group (COG) phase II study. J Clin Oncol 28(33):4969-4975.
9. Yu AL, et al.; Children's Oncology Group (2010) Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med 363(14):1324-1334.
10. Rossi EA, Chang CH, Cardillo TM, Goldenberg DM (2013) Optimization of multivalent bispecific antibodies and immunocytokines with improved in vivo properties. Bioconjug Chem 24(1):63-71.
11. Gillies SD (2013) A new platform for constructing antibody-cytokine fusion proteins (immunocytokines) with improved biological properties and adaptable cytokine activity. Protein Eng Des Sel 26(10):561-569.
12. Mühlradt PF, Opitz HG (1982) Clearance of interleukin 2 from the blood of normal and T cell-depleted mice. Eur J Immunol 12(11):983-985.
13. Freeman DJ, et al. (2012) Tumor penetration and epidermal growth factor receptor saturation by panitumumab correlate with antitumor activity in a preclinical model of human cancer. Mol Cancer 11:47.
14. Weiner LM, Surana R, Wang S (2010) Monoclonal antibodies: Versatile platforms for cancer immunotherapy. Nat Rev Immunol 10(5):317-327.
15. Wittrup KD, Thurber GM, Schmidt MM, Rhoden JJ (2012) Practical theoretic guidance for the design of tumor-targeting agents. Methods Enzymol 503:255-268.
16. Franciszkiewicz K, Boissonnas A, Boutet M, Combadière C, Mami-Chouaib F (2012) Role of chemokines and chemokine receptors in shaping the effector phase of the antitumor immune response. Cancer Res 72(24):6325-6332.
17. Wolpe SD, et al. (1989) Identification and characterization of macrophage inflammatory protein 2. Proc Natl Acad Sci USA 86(2):612-616.
18. Baudino L, et al. (2008) Crucial role of aspartic acid at position 265 in the CH2 domain for murine IgG2a and IgG2b Fc-associated effector functions. J Immunol 181(9):6664-6669.
19. Kourtis IC, et al. (2013) Peripherally administered nanoparticles target monocytic myeloid cells, secondary lymphoid organs and tumors in mice. PLoS ONE 8(4):e61646.
20. Guilliams M, Bruhns P, Saeys Y, Hammad H, Lambrecht BN (2014) The function of Fcaγ receptors in dendritic cells and macrophages. Nat Rev Immunol 14(2):94-108.
21. Boyman O, Sprent J (2012) The role of interleukin-2 during homeostasis and activation of the immune system. Nat Rev Immunol 12(3):180-190.
22. Rao BM, Driver I, Lauffenburger DA, Wittrup KD (2004) Interleukin 2 (IL-2) variants engineered for increased IL-2 receptor alpha-subunit affinity exhibit increased potency arising from a cell surface ligand reservoir effect. Mol Pharmacol 66(4):864-869.
23. Neal ZC, et al. (2004) Enhanced activity of hu14.18-IL2 immunocytokine against murine NXS2 neuroblastoma when combined with interleukin 2 therapy. Clin Cancer Res 10(14):4839-4847.
24. Ebbinghaus C, et al. (2005) Engineered vascular-targeting antibody-interferon-gamma fusion protein for cancer therapy. Int J Cancer 116(2):304-313.
25. Hemmerle T, Neri D (2014) The dose-dependent tumor targeting of antibody-IFNγ fusion proteins reveals an unexpected receptor-trapping mechanism in vivo. Cancer Immunol Res 2(6):559-567.
26. Kendra K, Malkovska V, Allen M, Guzman J, Albertini M (1999) In vivo binding and antitumor activity of Ch14.18. J Immunother 22(5):423-430.
27. Gillies SD, Young D, Lo KM, Roberts S (1993) Biological activity and in vivo clearance of antitumor antibody/cytokine fusion proteins. Bioconjug Chem 4(3):230-235.
28. Shanafelt AB, et al. (2000) A T-cell-selective interleukin 2 mutein exhibits potent antitumor activity and is well tolerated in vivo. Nat Biotechnol 18(11):1197-1202.
29. Maddatu TP, Grubb SC, Bult CJ, Bogue MA (2012) Mouse phenome database (MPD). Nucleic Acids Res 40(database issue):D887-D894.
30. Patel D, et al. (2007) Generation and characterization of a therapeutic human antibody to melanoma antigen TYRP1. Hum Antibodies 16(3-4):127-136.
31. Johnson EE, et al. (2008) Intratumoral immunocytokine treatment results in enhanced antitumor effects. Cancer Immunol Immunother 57(12):1891-1902.
32. Yang RK, et al. (2012) Intratumoral hu14.18-IL-2 (IC) induces local and systemic antitumor effects that involve both activated T and NK cells as well as enhanced IC retention. J Immunol 189(5):2656-2664.
33. Marabelle A, Kohrt H, Caux C, Levy R (2014) Intratumoral immunization: A new paradigm for cancer therapy. Clin Cancer Res 20(7):1747-1756.
34. Halin C, et al. (2002) Enhancement of the antitumor activity of interleukin-12 by targeted delivery to neovasculature. Nat Biotechnol 20(3):264-269.
35. Garcin G, et al. (2014) High efficiency cell-specific targeting of cytokine activity. Nat Commun 5:3016.